Serological markers for hepatocellular carcinoma - Modern trends

Central-European Journal of Immunology

Volumn 30, Issue 1-2, 2005, Pages 32-36

  Madaliński, Kazimierz ^a   Jończyk, Maria ^a   Rybczyńska, Jolanta ^a   Wawrzynowicz Syczewska, Marta ^b   Boroń Kaczmarska, Anna ^b  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Alpha fetopmtein; Alpha fiicosidase; Anti p53 antibodies; Costs of hcc surveillance; Hepatocellular carcinoma (HCC)

Indexed keywords

ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; PROTEIN P53;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; STAINING;

EID: 33747276536     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Wawrzynowicz-Syczewska M, Leonciuk A, Jurczyk K, et al. (2002): Increased incidence of hepatocellular carcinoma (in Polish). Pol Merk Lek 13: 100-102.
2. El Serag HB (2002): Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36: 574-583.
3. WHO.int/whr/2004
4. Di Bisceglie AM (1997): Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S-38S.
5. Center of Oncology-Institute, Warsaw - reports.
6. National Institute of Hygiene, Warsaw - epidemiological reports.
7. Fattovich G, Giustina G, Degos F, et al. (1997): Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472.
8. Bruix J, Sherman M, Llovet JM (2001): Clinical management of hepatocellular carcinoma. J Hepatol 35: 421-430.
9. Bolondi L, Sofia S, Siringo S, et al. (2001): Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259.
10. Szymendera JJ, Góźdź SS (1995): The value of circulating tumour markers in diagnosis and management of cancer patients (in Polish). Nowotwory 45: 369-383.
11. Kulpa J, Rychlik U (2004): Tumor markers in laboratory diagnostics (in Polish). Badanie i Diagnoza 10: 9-14.
12. Bergstrand CG, Czar B (1956): Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 8: 174-179.
13. Abelev G, Assecritova I, Kraevsky N (1967): Embryonal serum α-globulin in cancer patients. Diagnostic value. Int J Cancer 2: 551-558.
14. Masopust J, Kithier K, Radl J, et al. (1968): Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer 1968; 3: 364-373.
15. Kew M (2002): Milestones in liver disease. J Hepatol 37: 172-175.
16. Giardina M, Matarazzo M, Varriale A (1992): Serum alpha-L-fucosidase: a useful marker in the diagnosis of hepatocellular carcinoma. Cancer 70: 1044-1048.
17. Bayati N, Silverman AL, Gordon S.C. (1998): Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 93: 2452-2456.
18. Tong MJ, Blatt LM, Kao VW (2001): Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 16: 553-559.
19. Trevisani F, D'Intino PE, Morselli-Rabate AM, et al. (2001): Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575.
20. Imberti D, Fornari F, Sbolli G, et al. (1993): Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol 28: 540-544.
21. Tremolda R, Benevegnu L, Drago C, et al. (1989): Early detection of hepatocellular carcinoma in patients with cirrhosis by α-fetoprotein, ultrasound and fine-needle biopsy. Hepatogastroenterol 36: 519-521.
22. Giardina M, Matarazzo M, Morante R, et al. (1998): Serum α-L-fucosidase avtivity and early detection of hepatocellular carcinoma. Cancer 83: 2468-2474.
23. Matsumura M, Shiratori Y, Niwa Y (1999): Presence of α-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma. J Hepatol 31: 332-339.
24. Yuen MF, Lai CL (2005): Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 19: 91-99.
25. th Falk Liver Week. Liver Diseases: Advances in Treatment and Prevention, Freiburg 17-19.10.2003.
26. Ma J, Gong Q, Lin M, et al. (2000): Combined five tumor markers in detecting primary carcinoma (Chinese, with English summary). Zhonghua Wai Ke Za Zhi 38: 14-16.
27. Deugnier Y, David V, Brissot P, et al. (1984): Serum α-L- fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology 4: 889-892.
28. Sztefko K, Kosowski K, Rogatko I, et al. (1998): Alpha-L-fucosidase activity in patients with ductal cholelithiasis (in Polish). Przeglad Lekarski 55: 124-127.
29. Jonczyk M, Rybczyńska J, Madaliński K (2005): Alfa-fucosidase (AFU) in patients with liver cirrhosis (in Polish). Advances in Immunopathology. Abstracts of papers presented at a Conference in Poznan (J. Zeromski, chairman), 23-24.09.2005, p.23.
30. Takahashi H, Saibara T, Iwamura S. (1994): Serum α-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 19: 1414-1417.
31. Kurek K (2005): Early recognition of hepatocellular carcinoma - the value of surveillance program of HCV infected patients with the risk of HCC. Doctor thesis, Centre of Oncology - Institute Marie Sklodowskiej-Curie, Warsaw.
32. Ishizuka H, Nakayama T, Matsuoka S (1999): Prediction of the development of hepatocellular carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 38: 927-931.
33. Hollstein M, Sidransky D, Vogelstein B (1991): p53 mutation in human cancers. Science 253: 49-53.
34. Soussi T, Legros Y, Lubin R, et al. (1994): Multifunctional analysis of p53 alternation in human cancer: a review. Int J Cancer 57: 1-9.
35. Schlichtholz B, Tredaniel J, Lubin R, et al. (1994): Analyses of p53 antibodies in sera of patients with lung carcinoma: the fine immunodominant regions in the p53 protein. Brit J Cancer 69: 809-816.
36. Huo TI, Wang XW, Forgues M, et al. (2001): Hepatitis B virus X mutants derived from hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20: 3620-3628.
37. Raedle J, Roth WK, Oremek G, et al. (1995): Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci 40: 2587-2594.
38. Ryder SD, Rizzi PM, Volkmann M (1996): Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 49: 295-299.